Solventum (NYSE:SOLV) Stock Rating Upgraded by Wall Street Zen

Solventum (NYSE:SOLV) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Several other equities analysts have also recently issued reports on SOLV. Jefferies Financial Group started coverage on Solventum in a research report on Thursday, September 11th. They issued a “hold” rating and a $80.00 price target on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Solventum in a report on Thursday, October 30th. BTIG Research upgraded Solventum from a “neutral” rating to a “buy” rating and set a $100.00 price target for the company in a research note on Tuesday, December 2nd. Zacks Research lowered shares of Solventum from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 1st. Finally, Piper Sandler boosted their price objective on shares of Solventum from $94.00 to $98.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Four analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Solventum presently has an average rating of “Hold” and an average target price of $87.00.

Solventum Stock Up 0.2%

SOLV stock opened at $82.96 on Friday. The company has a market cap of $14.39 billion, a price-to-earnings ratio of 9.56, a price-to-earnings-growth ratio of 8.76 and a beta of 0.25. The company has a fifty day moving average price of $75.96 and a 200 day moving average price of $74.42. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14. Solventum has a 12 month low of $60.70 and a 12 month high of $88.20.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Thursday, November 6th. The company reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.43 by $0.07. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The company had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.05 billion. During the same period last year, the firm posted $1.64 EPS. Solventum’s revenue for the quarter was up .7% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. Sell-side analysts expect that Solventum will post 6.58 earnings per share for the current year.

Solventum declared that its Board of Directors has authorized a share buyback program on Thursday, November 20th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the company to buy up to 7.5% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Institutional Investors Weigh In On Solventum

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Measured Wealth Private Client Group LLC acquired a new position in shares of Solventum during the 3rd quarter worth $25,000. CYBER HORNET ETFs LLC purchased a new stake in Solventum during the second quarter worth about $28,000. Deseret Mutual Benefit Administrators boosted its holdings in Solventum by 78.7% during the third quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock worth $27,000 after buying an additional 163 shares in the last quarter. Barrett & Company Inc. grew its position in Solventum by 206.2% during the second quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock worth $30,000 after buying an additional 268 shares during the period. Finally, MUFG Securities EMEA plc purchased a new position in Solventum in the second quarter valued at about $31,000.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.